- Home
- ITRM vs BRNS Comparison
ITRM vs BRNS Comparison
Compare ITRM & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- BRNS
- Stock Information
- Founded
- ITRM 2015
- BRNS 2016
- Country
- ITRM Ireland
- BRNS United Kingdom
- Employees
- ITRM N/A
- BRNS N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- BRNS Health Care
- Exchange
- ITRM Nasdaq
- BRNS Nasdaq
- Market Cap
- ITRM 36.3M
- BRNS 38.7M
- IPO Year
- ITRM 2018
- BRNS 2021
- Fundamental
- Price
- ITRM $0.97
- BRNS $1.00
- Analyst Decision
- ITRM Strong Buy
- BRNS Strong Buy
- Analyst Count
- ITRM 2
- BRNS 2
- Target Price
- ITRM $7.00
- BRNS $3.00
- AVG Volume (30 Days)
- ITRM 515.1K
- BRNS 49.6K
- Earning Date
- ITRM 05-13-2025
- BRNS 05-07-2025
- Dividend Yield
- ITRM N/A
- BRNS N/A
- EPS Growth
- ITRM N/A
- BRNS N/A
- EPS
- ITRM N/A
- BRNS N/A
- Revenue
- ITRM N/A
- BRNS $14,969,000.00
- Revenue This Year
- ITRM N/A
- BRNS N/A
- Revenue Next Year
- ITRM $108.39
- BRNS N/A
- P/E Ratio
- ITRM N/A
- BRNS N/A
- Revenue Growth
- ITRM N/A
- BRNS 4381.74
- 52 Week Low
- ITRM $0.81
- BRNS $0.64
- 52 Week High
- ITRM $3.02
- BRNS $2.14
- Technical
- Relative Strength Index (RSI)
- ITRM 45.57
- BRNS 54.11
- Support Level
- ITRM $0.93
- BRNS $0.97
- Resistance Level
- ITRM $1.05
- BRNS $1.11
- Average True Range (ATR)
- ITRM 0.05
- BRNS 0.11
- MACD
- ITRM 0.01
- BRNS 0.01
- Stochastic Oscillator
- ITRM 50.00
- BRNS 74.78
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.